Altimmune's 2026 Catalyst Calendar: MASH Phase 3 Launch and AUD Data Set Up Pivotal Year

What happened

Altimmune enters 2026 with a dense catalyst schedule, including the initiation of its registrational MASH Phase 3 trial and data from the RECLAIM AUD study, which together will test pemvidutide's multi-indication promise. The company secured FDA Breakthrough Therapy Designation in MASH and raised $75M in January 2026, boosting pro-forma cash to ~$285M and extending runway through Phase 3 startup. Despite strong non-invasive fibrosis signals and lean-mass preservation advantages from Phase 2, the stock has declined ~12% over the past year as investors remain skeptical about funding and competitive positioning in the crowded GLP-1 landscape. The market prices the stock at a modest premium to cash, implying limited value assigned to obesity and AUD optionality. Over the next 12-18 months, successful MASH Phase 3 initiation and a partnership for obesity could unlock significant upside, while delays or weak data would pressure the stock toward cash value.

Implication

Altimmune's near-$6/share valuation embeds limited credit for obesity and AUD programs, making it a high-risk, high-reward binary bet on MASH Phase 3 and partnership execution. The base case of $9 assumes timely MASH initiation and selective partnering to avoid dilution, while the bear case of $3 reflects funding failures or negative data. The next six months are critical: confirm MASH Phase 3 start and any obesity partnership. Position sizing should reflect binary risk, but for tolerant investors, the current price provides margin of safety if catalysts materialize.

Thesis delta

The market narrative has shifted from obesity-driven upside to a MASH-centric story, with recent positive data triggering a 'sell the news' response, indicating higher investor skepticism. The new article reinforces that 2026 is a pivotal execution year where MASH Phase 3 launch and AUD data will determine whether pemvidutide is de-risked or stranded. This shifts focus from scientific promise to capital discipline and partnership timelines.